PT  - JOURNAL ARTICLE
AU  - Lisa K.  Stamp
AU  - William Taylor
AU  - Angelo Gaffo
TI  - Variability in Urate-lowering Therapy Prescribing: A Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) Physician Survey
AID  - 10.3899/jrheum.200347
DP  - 2020 Oct 01
TA  - The Journal of Rheumatology
PG  - jrheum.200347
4099  - http://www.jrheum.org/content/early/2020/09/28/jrheum.200347.short
4100  - http://www.jrheum.org/content/early/2020/09/28/jrheum.200347.full
AB  - Gout is common in people with chronic kidney disease (CKD) and its treatment is frequently suboptimal in this special population due to concerns over adverse events and/or efficacy of medications. There is controversy about the use of urate-lowering therapy (ULT) in those with CKD and lack of agreement about the dosing of allopurinol, the recommended first-line ULT1,2.